CAN
TBPH icon

Cetera Advisor Networks’s Theravance Biopharma TBPH Stock Holding History

Cetera Advisor Networks’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-604
Closed -$13K – 2831
2020
Q2 		$13K Buy
+604
New +$15.5K ﹤0.01% 2616

Other funds holding TBPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Cetera Advisor Networks's TBPH Position: Q3 2020 in Review

Cetera Advisor Networks sold out of Theravance Biopharma (TBPH) in Q3 2020, closing a stake of 604 shares — an estimated $13K sold.

Cetera Advisor Networks first reported a position in TBPH in Q2 2020 and held it in 1 quarter. The position peaked at $13K in Q2 2020. 118 funds tracked by Wall St. Rank hold TBPH as of Q3 2020.

  • Cetera Advisor Networks reported no remaining Theravance Biopharma position as of Q3 2020 after selling out during the quarter.
  • Cetera Advisor Networks sold 604 Theravance Biopharma shares in Q3 2020, an estimated $13K.
  • Cetera Advisor Networks first reported a position in Theravance Biopharma in Q2 2020 and held it in 1 quarter.
  • Cetera Advisor Networks's Theravance Biopharma position peaked at $13K in Q2 2020.
  • 118 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2020.

Based on Cetera Advisor Networks's 13F filing for Q3 2020, filed 13 Nov 2020.